Zobrazeno 1 - 10
of 13
pro vyhledávání: '"James E. Schiller"'
Autor:
James E. Schiller, Elizabeth Groeber, Joseph A Tweed, Ang Liu, Violet Lee, Mehran F. Moghaddam, Gregory S. Walker
Publikováno v:
Bioanalysis. 8:259-264
Boston Society's 11th Annual Applied Pharmaceutical Analysis conference, Hyatt Regency Hotel, Cambridge, MA, USA, 14–16 September 2015 The Boston Society’s 11th Annual Applied Pharmaceutical Analysis (APA) conference took place at the Hyatt Regen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2559736ee5c08b5d210ef6f72c1fc439
https://doi.org/10.4155/bio.15.250
https://doi.org/10.4155/bio.15.250
Autor:
Thomas S. Rush, Hussein Tawbi, Yongqi Deng, Wen-Jen Hwu, Paul Kirschmeier, Ryan J. Sullivan, Joseph Rubino, Ahmed A. Samatar, Lidia Robert, Gerald W. Shipps, Keith T. Flaherty, Donna Carr, Peter C.C. Fong, Antoni Ribas, Patrick Chun, Brian Long, Eric H. Rubin, Priya Dayananth, Ramesh K. Ramanathan, Ronnie Shapira-Frommer, Stergios J. Moschos, Blanca Homet Moreno, W. Robert Bishop, Alan B. Cooper, James E. Schiller, Alex A. Adjei, Nathan R. Miselis, Da Zhang
Publikováno v:
JCI Insight, Vol 3, Iss 4 (2018)
JCI insight, vol 3, iss 4
JCI insight, vol 3, iss 4
BACKGROUND. Constitutive activation of ERK1/2 occurs in various cancers, and its reactivation is a well-described resistance mechanism to MAPK inhibitors. ERK inhibitors may overcome the limitations of MAPK inhibitor blockade. The dual mechanism inhi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f1125084220541ce8d767feec5c05a4
https://doaj.org/article/675b9e9f9e9e4e0f87e9c28de4f3db4b
https://doaj.org/article/675b9e9f9e9e4e0f87e9c28de4f3db4b
Autor:
Bhavna Kantesaria, Bharath Kumar, Paul Statkevich, Christine McCrary Sisk, David L. Cutler, Teddy Kosoglou, James E. Schiller, Mary E. Hanson
Publikováno v:
Clinical Pharmacology in Drug Development. 4:56-62
Purpose To evaluate the potential effects of vorapaxar on the pharmacokinetics and safety of rosiglitazone. Methods This was an open-label, two-period, two-treatment, fixed-sequence study in 18 healthy subjects. On Day 1, Period 1, subjects received
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::15eb316a438c1fd54f39c0ee953eba36
https://doi.org/10.1002/cpdd.133
https://doi.org/10.1002/cpdd.133
Autor:
Bharath Kumar, Jack Tseng, James E. Schiller, Larisa Reyderman, Kenneth Kim, Fengjuan Xuan, David L. Cutler, Teddy Kosoglou, Alan G. Meehan
Publikováno v:
Clinical Pharmacology in Drug Development. 2:223-230
This randomized, open-label, parallel group study examined the effects of food, antacid, and age on the pharmacokinetics of vorapaxar. In total, 101 subjects were enrolled including 83 young adults (18–45 years) and 18 elderly subjects (>65 years).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a7843e6eaba4e071affcc73111b27d48
https://doi.org/10.1002/cpdd.30
https://doi.org/10.1002/cpdd.30
Autor:
Paul Statkevich, James E. Schiller, Amy O. Johnson-Levonas, Sophia Young, Bharath Kumar, David L. Cutler, Fengjuan Xuan, Teddy Kosoglou
Publikováno v:
The Journal of Clinical Pharmacology. 53:540-549
This randomized, open-label, parallel-group study evaluated the effects of multiple-dose ketoconazole or rifampin on the single- and multiple-dose pharmacokinetics of vorapaxar. Healthy subjects randomly received one of the following three treatments
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::51a9dcef1fdaf489d626bbaff2e5bd16
https://doi.org/10.1002/jcph.20
https://doi.org/10.1002/jcph.20
Autor:
James E. Schiller, Fengjuan Xuan, Paul Statkevich, Amy O. Johnson-Levonas, Teddy Kosoglou, David L. Cutler, Yali Zhu
Publikováno v:
Clinical Pharmacology in Drug Development. 2:90-98
Vorapaxar is a novel orally active thrombin receptor antagonist selective for the PAR-1 receptor. This open-label, single-center, fixed-sequence, 2-period, 2-treatment study assessed the pharmacokinetics and pharmacodynamics of single-dose digoxin in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::54929a1c6a71bc2d97570c8b6e92cdfe
https://doi.org/10.1002/cpdd.11
https://doi.org/10.1002/cpdd.11
Autor:
Fengjuan Xuan, Paul Statkevich, Ronald B. Langdon, Craig Trusley, Teddy Kosoglou, David L. Cutler, Bharath Kumar, Richard A. Preston, James E. Schiller
Publikováno v:
European Journal of Clinical Pharmacology. 68:1501-1508
To determine whether hepatic impairment has an effect on the pharmacokinetics (PK) of vorapaxar or M20, its main pharmacologically active metabolite.This was an open-label study in which a single 40-mg oral dose of vorapaxar was administered to patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5f4605c87f5296f0e20b268b3fcaae3
https://doi.org/10.1007/s00228-012-1269-7
https://doi.org/10.1007/s00228-012-1269-7
Autor:
Stephen E. Maxwell, David L. Cutler, Teddy Kosoglou, Sophia Young, Lisa K. Jennings, Fengjuan Xuan, Jinglan Pei, Alan G. Meehan, Claudia Kasserra, Larisa Reyderman, James E. Schiller
Publikováno v:
European Journal of Clinical Pharmacology. 68:291-300
Vorapaxar, a novel antiplatelet agent in advanced clinical development for the prevention and treatment of atherothrombotic disease, is a potent, orally bioavailable thrombin receptor antagonist selective for the protease-activated receptor 1 (PAR-1)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9df0cbe5df595f019f6f899ba0415517
https://doi.org/10.1007/s00228-011-1127-z
https://doi.org/10.1007/s00228-011-1127-z
Publikováno v:
Journal of Pharmaceutical and Biomedical Analysis. 55:349-359
SCH 530348 is a safe and effective oral anti-platelet agent for patients with acute coronary syndrome. Clinical study results suggest that SCH 530348 dosage at 20 mg or 40 mg is feasible to achieve rapid maximum platelet inhibition following an acute
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee6aa22f0acb489ddd4fbfee5cf9d7ed
https://doi.org/10.1016/j.jpba.2011.01.045
https://doi.org/10.1016/j.jpba.2011.01.045
Autor:
Teddy, Kosoglou, Bharath, Kumar, Paul, Statkevich, James E, Schiller, Bhavna, Kantesaria, Mary E, Hanson, Christine McCrary, Sisk, David L, Cutler
Publikováno v:
Clinical pharmacology in drug development. 4(1)
To evaluate the potential effects of vorapaxar on the pharmacokinetics and safety of rosiglitazone.This was an open-label, two-period, two-treatment, fixed-sequence study in 18 healthy subjects. On Day 1, Period 1, subjects received a single dose of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f4cd0d6748cf731083ef90e26351e7e1
https://pubmed.ncbi.nlm.nih.gov/27128003
https://pubmed.ncbi.nlm.nih.gov/27128003